1st Patient Enrolled in Pivotal Clinical Trial Evaluating the Hydrus Microstent in Standalone MIGS for Mild to Moderate Glaucoma
The FRONTIER trial will build on long-term findings from the Hydrus HORIZON five-year pivotal trial, which showed a 47% reduction in visual field loss, sustained reduction in medication use, and over 60% reduction in subsequent, more invasive glaucoma surgery.